Please use this identifier to cite or link to this item:
Title: Impact of the 13-valent conjugated pneumococcal vaccine on the direct costs of invasive pneumococcal disease requiring hospital admission in children aged < 5 years. A prospective study
Author: Hernández, Sergi
Navas, Encarna
Aznar Lou, Ignacio
Ciruela, Pilar
García García, Juan José
Moraga Llop, Fernando A.
Muñoz Almagro, Carmen
Codina Grau, Maria Gemma
de Sevilla, Mariona F.
González Peris, Sebastià
Esteva, Cristina
Planes, Ana María
Izquierdo, Conchita
Martínez Osorio, Johanna
Campins Martí, Magda
Uriona, Sonia
Salleras i Sanmartí, Lluís
Serrano Blanco, Antoni
Jané, Mireia
Domínguez García, Àngela
Keywords: Vacuna antipneumocòccica
Pneumococcal vaccine
Issue Date: 15-Jul-2020
Publisher: MDPI
Abstract: The lack of invasive pneumococcal disease (IPD) cost studies may underestimate the effect of pneumococcal polysaccharide conjugated vaccines (PCV). The objective of this study was to estimate the direct costs of hospitalized IPD cases. A prospective study was made in children aged <5 years diagnosed with IPD in two high-tech hospitals in Catalonia (Spain) between 2007-2009 (PCV7 period) and 2012-2015 (PCV13 period). Costs were calculated according to 2014 Catalan Health Service rates using diagnostic-related groups. In total, 319 and 154 cases were collected, respectively. Pneumonia had the highest cost (65.7% and 62.0%, respectively), followed by meningitis (25.8% and 26.1%, respectively). During 2007-2015, the costs associated with PCV7 serotypes (Pearson coeffcient (Pc) = 􀀀0.79; p = 0.036) and additional PCV13 serotypes (Pc = 􀀀0.75; p = 0.05) decreased, but those of other serotypes did not (Pc = 0.23 p = 0.62). The total mean cost of IPD increased in the PCV13 period by 31.4% (¿3016.1 vs. ¿3963.9), mainly due to ICU stay (77.4%; ¿1051.4 vs. ¿1865.6). During the PCV13 period, direct IPD costs decreased due to a reduction in the number of cases, but cases were more severe and had a higher mean cost. During 2015, IPD costs increased due to an increase in the costs associated with non-PCV13 serotypes and serotype 3 and this requires further investigation.
Note: Reproducció del document publicat a:
It is part of: Vaccines, 2020, vol. 8, num. 3
Related resource:
ISSN: 2076-393X
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
702692.pdf903.44 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons